Institution identification

Institution ID

3331504

Institution full name and acronym

ViiV Healthcare

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Comprehensive Assessment of Adverse Events and Overall Safety Profile in HIV Positive Patients Treated with Dolutegravir as Compared to Other Integrase Strand Transfer Inhibitors or Darunavir (207832)
A multi-site observational study to assess safety and effectiveness of prenatal exposure to Dolutegravir in pregnant individuals living with HIV (212976)
A prospective observational cohort study to monitor for hepatotoxicity and regimen discontinuation due to liver related adverse events among People with HIV, initiating Cabotegravir + Rilpivirine regimens (215162)
Abacavir Usage Patterns and Trends in Hypersensitivity Reactions (HSR) in the EuroSIDA cohort (206307)
Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Meta-analysis of Data from Clinical Trials (207263)
An Evaluation of the Safety of Lamivudine in HIV Positive Patients with Renal Impairment (208948)
An evaluation of weight gain in patients treated with dolutegravir and other core agents (209025)
An Evaluation of Weight Gain in Patients Treated with Dolutegravir vs. Other Core Agents (208943)
C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance (215160)
CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe (221935)
CAB LA PrEP Cohort: Prospective Cohort Study to Assess Effectiveness and Safety of, and Adherence and Resistance to Cabotegravir for Pre-Exposure Prophylaxis in the United States (217671)
CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047)
Comparison of Dolutegravir Effectiveness vs. Other Anchor Agent Effectiveness among Hepatitis C Virus Co-infected patients in the OPERA® Observational Database (207833)
Descriptive Analysis of Neuropsychiatric Diagnoses in Patients taking Dolutegravir in the OPERA® Observational Database (205846)
Development of AntiRetroviral Therapy in Africa (DART) study post hoc safety data analysis comparing safety outcomes of study participants with baseline creatinine clearance of 30-49 mL/min vs participants with creatinine clearance of ≥50 mL/min
DOLOMITE EPPICC Study: Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir: Data from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) (208613)
DOLOMITE NEAT ID Network Study: A prospective, multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women (208759)
Dolutegravir use and incidence of prediabetes and type 2 diabetes mellitus (209368)
Dolutegravir Use and Predictors of CNS events: Meta-analysis of Data from Phase III/IIIb Clinical Trials
Drug Utilization, Adherence, Effectiveness and Resistance: A Prospective Observational Cohort Study in People living with HIV (PLWH) initiating ARV regimen CAB+RPV LA in Collaboration with EuroSIDA (215161)
Patient characteristics, Adherence, and Clinical Outcomes among People Living with HIV (PLWH), Initiating Cabotegravir + Rilpivirine LA Regimen in the OPERA Cohort
Post-marketing safety analyses for multiple marketed products in collaboration with the D:A:D study (206247)
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir Long Acting (CAB LA): Data from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) (215163)
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir: Data from The Antiretroviral Pregnancy Registry (APR) (215325)
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir: Data from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) (206254)
Prenatal Exposure to Dolutegravir and Pregnancy and Neonatal Outcomes: Data from Antiretroviral Pregnancy Registry (206242)
Prospective Study to Assess Usage, Adherence, Effectiveness of Cabotegravir LA for Pre-Exposure Prophylaxis in the United States in the OPERA Cohort (219844)
Rates of Suspected Hypersensitivity Reaction in HIV infected Adult treatment populations screened HLA-B*5701 negative prior to commencing Abacavir therapy: Meta-analysis of Data from GlaxoSmithKline and ViiV Healthcare Sponsored Clinical Trials (207831)
Rates of Suspected Hypersensitivity Reaction to Abacavir and Associated Rates of HLA-B*5701 Testing (206206)
‘COMBINE-2’: Real-world evidence for effectiveness of Two Drug Regimen, Antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor (207859)